OncoViews
@OncoViews
Uniting HCPs to share the latest advances in #oncology. Making medical education accessible to all. Content on this channel is for informational purposes only.
ID:1243999338919079937
https://www.oncoviews.com 28-03-2020 20:32:27
3,8K Tweets
1,7K Followers
880 Following
Be sure to catch Berna Özdemir (Insel Gruppe) to discuss the latest developments in #ProstateCancer following the #ASCO congress at our next roundtable!
She'll be joined by Giuseppe Banna and our host, Alex Friedlaender.
⏰ 5th June at 5.30PM CEST
Tune in for free ⬇️
Join us for the OncoViews meeting to stay updated on the latest news from #ASCO24 We'll be discussing the latest developments in genitourinary cancers, including #prostatecancer , #urothelialcancer , and #renalcancer . Register now and join the conversation!
How do we assess #HER2 in immunohistochemistry for lung and lower gastrointestinal cancers?
Hear from Florian Lordick and Hochmair Maximilian at our recent roundtable with Ilaria Colombo as our host!
Catch the full discussion for free ⬇️
OncoAlert
The FDA Oncology has granted accelerated approval to lisocabtagene maraleucel for adults with relapsed or refractory #FollicularLymphoma who have received two or more prior lines of systemic therapy 💊
See the full press release ⬇️
📣 Our paper “Recommendations for reporting tissue & circulating tumour (ct)DNA NGS results in NSCLC” is online British Journal of Cancer nature Umberto Malapelle Alfredo Addeo MD prof. Ola Khorshid Hochmair Maximilian Natasha Leighl, Nir Peled, Egbert Smit, & a great team
International Society of Liquid Biopsy
nature.com/articles/s4141…
Join Alex Friedlaender for an exciting roundtable on the latest advances in prostate, renal cell, and urothelial cancer following the #ASCO congress. He'll be joined by renowned experts, Berna Özdemir and Giuseppe Banna!
⏰ 5th June at 5.30 PM CEST
Join the discussion for free ⬇️
FDA has granted accelerated approval to lisocabtagene maraleucel for adults with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic therapy.
fda.gov/drugs/resource…
#OCENewsBurst
We hope you enjoyed last night's debate on CAR T-cells vs bispecifics for #DLBCL with renowned experts Federico Simonetta (HUG), Thorsten Zenz, and Maria Cristina Pirosa.
Here's a quick snippet of Thorsten Zenz's case for bispecifics.
Catch the full discussion for free ⬇️
🚨 TONIGHT
Don't miss an insightful debate on CAR T-cells vs bispecifics for #DLBCL with Maria Cristina Pirosa (@EnteOspedaliero) as our host, alongside Federico Simonetta (@hug_ge) and Thorsten Zenz (@Unispital_USZ).
Join us for free at 5PM and share your insights ⬇️
🚨 TONIGHT
Don't miss an insightful debate on CAR T-cells vs bispecifics for #DLBCL with Maria Cristina Pirosa (@EnteOspedaliero) as our host, alongside Federico Simonetta (@hug_ge) and Thorsten Zenz (@Unispital_USZ).
Join us for free at 5PM and share your insights ⬇️
Join Federico Simonetta as he presents his case for CAR T-cells against bispecifics as the greater treatment approach for DLBCL at next week's roundtable debate!
He'll be joined by Thorsten Zenz & Maria Cristina Pirosa.
⏰ 14th May at 5PM CEST
Register now ⬇️
#Bispecifics have emerged as a promising therapeutic option for those with diffuse large B-cell lymphoma ( #DLBCL ).
Catch Thorsten Zenz next week, alongside Federico Simonetta and Maria Cristina Pirosa, to debate this treatment approach against #CAR T-cells!
Register below ⬇️
MARS 2 trial results show that extended pleurectomy decortication & chemotherapy were associated with worse survival & a higher rate of adverse events in those with resectable pleural #mesothelioma compared w/ chemotherapy alone.
The Lancet Respiratory Medicine by Eric Lim & colleagues ⬇️
#Bispecifics have emerged as a promising therapeutic option for those with diffuse large B-cell lymphoma ( #DLBCL ).
Catch Thorsten Zenz next week, alongside Federico Simonetta and Maria Cristina Pirosa, to debate this treatment approach against #CAR T-cells!
Register below ⬇️
The Swissmedic has approved abemaciclib in combination with endocrine therapy for the adjuvant treatment of adults with HR-positive, #HER2 -negative, lymph node-positive, early-stage #BreastCancer with a high risk of recurrence based on lymph node status, primary tumor size, and
Join Federico Simonetta as he presents his case for CAR T-cells against bispecifics as the greater treatment approach for DLBCL at next week's roundtable debate!
He'll be joined by Thorsten Zenz & Maria Cristina Pirosa.
⏰ 14th May at 5PM CEST
Register now ⬇️
Which is the best treatment approach for #DLBCL : CAR T-cells or bispecifics?
Join our host, Maria Cristina Pirosa, alongside Thorsten Zenz and Federico Simonetta, for an insightful debate on this very question!
⏰ 14th May at 5PM CEST
Join the discussion for free ⬇️